Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

被引：21
作者：
Cutolo, Maurizio [1 ]
Meroni, Marianna
机构：
[1] Univ Genoa, Dept Internal Med, Res Labs, Viale Benedetto XV 6, I-16132 Genoa, Italy
来源：
JOURNAL OF INFLAMMATION RESEARCH | 2013年 / 6卷
关键词：
Janus kinase inhibitors; tofacitinib; rheumatoid arthritis; kinases; small molecules inhibitors; intracellular signaling;
D O I：
10.2147/JIR.S35901
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected patients by synthesizing several inflammatory mediators, including cytokines that initiate intracellular signaling. Recently, small molecule inhibitors of transduction and transcription signals that influence the intracellular pathways (such as the Janus kinase [ JAK] family of tyrosine kinases) have been tested for RA treatment. Four members of the JAK family are known: JAK1, JAK2, JAK3, and TyK2. JAK1/JAK3 constitutively binds to the cytoplasmic portion of the cytokine receptor -the common gamma chain -that represents a common subunit of several cytokines involved in T-cell and natural killer cell development, as well as in B-cell activation. Tofacitinib is an oral JAK inhibitor that is now available and effective in RA treatment, as shown in multiple Phase II and Phase III clinical trials. However, long-term safety data and comparisons with other disease-modifying antirheumatic drugs and small molecule inhibitors are necessary to better determine the role of tofacitinib in RA.
引用
收藏
页码：129 / 136
页数：8
相关论文
共 37 条
  • [1] McInnes I.B., Schett G., The pathogenesis of rheumatoid arthritis, N Engl J Med, 365, 23, pp. 2205-2219, (2011)
  • [2] Emery P., Dorner T., Optimising treatment in rheumatoid arthritis: A review of potential biological markers of response, Ann Rheum Dis, 70, 12, pp. 2063-2070, (2011)
  • [3] Weinblatt M.E., Trentham D.E., Fraser P.A., Et al., Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis, Arthritis Rheum, 31, 2, pp. 167-175, (1988)
  • [4] Cutolo M., The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potential, Ther Adv Musculoskelet Dis, 5, 1, pp. 3-11, (2013)
  • [5] Fleischmann R., Novel small-molecular therapeutics for rheumatoid arthritis, Curr Opin Rheumatol, 24, 3, pp. 335-341, (2012)
  • [6] Salgado E., Maneiro J.R., Carmona L., Gomez-Reino J.J., Safety profile of protein kinase inhibitors in rheumatoid arthritis: Systematic review and meta-analysis, Ann Rheum Dis, (2013)
  • [7] Leonard W.J., Role of Jak kinases and STATs in cytokine signal transduction, Int J Hematol, 73, 3, pp. 271-277, (2001)
  • [8] Ghoreschi K., Jesson M.I., Li X., Et al., Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550), J Immunol, 186, 7, pp. 4234-4243, (2011)
  • [9] Cheng H., Ross J.A., Frost J.A., Kirken R.A., Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity, Mol Cell Biol, 28, 7, pp. 2271-2282, (2008)
  • [10] Funakoshi-Tago M., Tago K., Kasahara T., Parganas E., Ihle J.N., Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway, Cell Signal, 20, 11, pp. 1995-2001, (2008)
1234